ClinicalTrials.gg
RecruitingNCT05710549Updated Jul 15, 2025

Understanding Brain Mechanisms Involved in Autobiographical Memory

An interventional study of high-density electroencephalography (hdEEG) and Transcranial alternating current stimulation (tACS) in Mild Cognitive Impairment, Alzheimer Disease and Memory Loss, sponsored by Lucie Bréchet. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by Lucie Bréchet · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Apr 2022, registered Jan 2023).
  • Started Apr 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Cognitive Dysfunction with a site in Switzerland — 17 open to participants now, 21 under way, 3 of them phase 3. Cognitive Dysfunction · Switzerland.

Planned enrollment
14th of 48
120 · median 56
Started
2022
with 2 others
No phase
38 of 61
13 open now
Primary completion
2027-05
later than 9 of 20 live
Registered
39th of 61
by date
Lead sponsor
2 of 61
Lucie Bréchet

Among the 61 studies in Cognitive Dysfunction with a site in Switzerland, this one is the 14th largest by planned enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2022, is one of 38 with no phase, reaches primary completion later than 9 of the 20 other live ones, and was the 39th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

17 of the 61 studies in Cognitive Dysfunction with a site in Switzerland are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Cognitive Dysfunction with a site in Switzerland, or all of them as a file.
02

Study summary

The overall objective of this project is to characterize the spatiotemporal dynamics of brain oscillations underpinning autobiographical memory (ABM) and the modulation of the memory network using non-invasive brain stimulation.

Read the detailed description

Accumulating evidence suggests that activity in distributed networks supporting ABM is altered even decades before the expected onset of clinical symptoms in Alzheimer's disease (AD). Robust network alterations associated with age-related memory and cognitive decline have been linked to abnormal oscillatory brain rhythmic activity and functional dysconnectivity. However, the detailed neural mechanisms are still poorly understood. The investigators propose to precisely characterize the underlying neurophysiological mechanisms that lead to behavioral and cognitive disturbances in ABM of MCI patients. Specifically, hdEEG will be used to characterize the sources and spatiotemporal dynamics of the neuronal activity involved in the ABM network of 40 mild cognitive impairment (MCI) patients and compare it to 40 age-matched, older healthy participants and 40 healthy young participants. The investigators will then apply non-invasive brain stimulation in the form of transcranial alternating current stimulation (tACS) to gain novel insights into the causal role of brain oscillations in the ABM network of MCI patients.

03

Conditions studied

  • Mild Cognitive Impairment
  • Alzheimer Disease
  • Memory Loss

Keywords

  • autobiographical memory (ABM)
  • high-density electroencephalography (EEG)
  • magnetic resonance imaging (MRI)
  • non-invasive brain stimulation (NIBS)
  • transcranial alternating current stimulation (tACS)
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cognitively-Unimpaired Younger and Older Adults

  • Age 18 to 35 years old (younger adults)
  • Age 55+ years old (older adults)
  • without any cognitive impairment (based on the : MoCA)
  • willing and capable to give for participation in the study after it has been thoroughly explained able
  • willing to comply with all study requirements informed consent form was signed

Mild Cognitive Impairment (MCI) patients

  • Age 55+ years old
  • Clinical Diagnosis of MCI
  • Confirmation of diagnosis will be made by the study MD based on a holistic consideration of the participant's cognitive evaluation and history
  • Mini-Mental State Examination (MMSE) ≥ 18 (Mild AD ≥ 21)
  • CDR ≥ .5
  • Demonstration or history of autobiographical memory impairments
  • On a stable dose of medications for memory loss including cholinesterase inhibitors (e.g. donepezil, rivastigmine) or memantine as defined as 6 consecutive weeks of treatment at an unchanging dose
  • Minimum of completed 8th-grade education
  • willing and capable to give informed consent for participation in the study after it has been thoroughly explained - note that to ensure this in the case of the MCI participants, a cut-off of MOCA score >18 will be applied
  • able and willing to comply with all study requirements informed consent form was signed

Exclusion criteria

Exclusion Criteria:

Cognitively-Unimpaired Younger and Older Adults

  • any cognitive impairment captured by the (MoCA) - score \< 26
  • major psychiatric co-morbidity including major depressive disorder, schizophrenia, or psychosis
  • blindness or other disabilities that prevent task performance
  • for undergoing MRI
  • Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement)

Mild Cognitive Impairment (MCI) patients

  • Age \< 55 years old
  • Any current diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depressive disorder)
  • Other than MCI, any history of other progressive or genetic neurologic disorder (e.g. Parkinson's disease, multiple sclerosis, tubular sclerosis) or acquired neurological disease (e.g. stroke, traumatic brain injury, tumor), including intracranial lesions
  • History of head trauma resulting in prolonged loss of consciousness
  • Current history of poorly controlled headaches including chronic medication for migraine prevention
  • History of fainting spells of unknown or undetermined etiology that might constitute seizures
  • History of seizures, diagnosis of epilepsy, or immediate (1st-degree relative) family history of epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist
  • Any unstable medical condition or chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) or study complication
  • contraindications to tACS, as recorded on a standardized screening questionnaire, which include a reported seizure within the past two years, use of neuroactive drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp
  • Contraindication for undergoing MRI or receiving tACS
  • Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement)
  • Any devices such as a pacemaker, medication pump, nerve stimulator, TENS unit, ventriculoperitoneal shunt unless cleared by the responsible covering MD
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    neurophysiological measurements

    40 cognitively-unimpaired healthy young adults (age 18-35 years old), 40 cognitively-unimpaired healthy older adults (age 55+ years old), and 40 age-matched patients with mild cognitive impairment (MCI) (age 55+ years old) will be assessed using high-density electroencephalography (hdEEG) to characterize the spatiotemporal dynamics of brain oscillations during personalized, autobiographical memory (ABM) tasks.

    Device: high-density electroencephalography (hdEEG)

  • Experimental
    neuropsychological examination

    40 MCI patients (age 55+ years old) will undergo 20min multi-channel protocols of transcranial alternating current stimulation; tACS (either gamma, beta, or ActiSham stimulation randomized across the three laboratory sessions) to modify cognitive functioning (MoCA score), and oscillatory brain activity during performing personalized, autobiographical memory (ABM) tasks and resting-state EEG.

    Device: Transcranial alternating current stimulation (tACS)

Interventions

  • Devicehigh-density electroencephalography (hdEEG)

    EEG will be recorded with a 257-channel EEG system (Geodesic Sensor Net, MegStim). An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek, Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touches the participant's scalp surface directly. Net application takes about 10 min to derive impedances to \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between 0.1-200 Hz. Vertex electrode Cz is used as an acquisition reference.

  • DeviceTranscranial alternating current stimulation (tACS)

    tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance.

06

What researchers measure

Primary outcomes

  1. Spatiotemporal dynamic changes measured with electroencephalography (hdEEG)

    Changes in spatiotemporal dynamics in different frequency bands (theta, alpha, beta, gamma) will be assessed with hdEEG

    Time frame: up to 30 minutes

  2. Cognitive Assessment

    The Montreal Cognitive Assessment (MOCA) will be administered to characterize the cognitive status

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
  • University of Geneva, Campus Biotech
    Geneva, Canton of Geneva 1202, Switzerland
    Recruiting
    • Lucie Bréchet, PhD · Contact
    • Lucie Bréchet, PhD · Principal investigator
    • Paul G Unschuld, Prof MD · Sub investigator
08

References and documents

Publications

  • Brechet L, Brunet D, Birot G, Gruetter R, Michel CM, Jorge J. Capturing the spatiotemporal dynamics of self-generated, task-initiated thoughts with EEG and fMRI. Neuroimage. 2019 Jul 1;194:82-92. doi: 10.1016/j.neuroimage.2019.03.029. Epub 2019 Mar 19. PubMed 30902640 ↗
  • Roehri N, Brechet L, Seeber M, Pascual-Leone A, Michel CM. Phase-Amplitude Coupling and Phase Synchronization Between Medial Temporal, Frontal and Posterior Brain Regions Support Episodic Autobiographical Memory Recall. Brain Topogr. 2022 Mar;35(2):191-206. doi: 10.1007/s10548-022-00890-4. Epub 2022 Jan 26. PubMed 35080692 ↗
  • Michel CM, He B. EEG source localization. Handb Clin Neurol. 2019;160:85-101. doi: 10.1016/B978-0-444-64032-1.00006-0. PubMed 31277878 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for May 2027, 60 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 60 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2023
First posted
Feb 2, 2023
StartActual
Apr 25, 2022
Primary completionEst.
May 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05710549
Lead sponsor
Lucie Bréchet
Responsible party
Lucie Bréchet (Dr., University of Geneva, Switzerland) — Sponsor-investigator
First posted
Feb 2, 2023
Start date
Apr 25, 2022
Primary completion
May 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Jul 15, 2025

Study contacts

Lucie Bréchet, PhD
Contact
lucie.brechet@unige.ch
+41 22 379 08 52
Lucie Bréchet, PhD
principal investigator · University of Geneva (UNIGE)
Paul G Unschuld, Prof. MD
study chair · Geneva University Hospitals (HUG)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion